Adjuvant dose-intense chemotherapy with peripheral blood stem cell support in stage II-III breast cancer with five to nine involved axillary lymph nodes

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 2, 1999, Pages 136-142

  Schwartzberg, Lee S ^a   Birch, Robert ^a   Tauer, Kurt W ^a   Leff, Richard ^a   Greco, F Anthony ^a   Hainsworth, John ^a   Raefsky, Eric ^a   McAneny, Barbara ^a   Weaver, Zebulon ^a   West, John ^a   Buckner, C Dean ^a,b   Weaver, Charles H ^a  

^a Clin Res Div Response Oncol I   (United States)

^b Response Oncology Inc   (United States)

Author keywords

5 9 positive nodes; Adjuvant high dose therapy

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; LEUKOCYTE TRANSFUSION; LIVER TOXICITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RADIATION PNEUMONIA; RECURRENT CANCER;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; FLUOROURACIL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 17144465348     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199904000-00006     Document Type: Article

References (31)

1. Jones RB, Holland JF, Bhardwaj S, et al. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 1987;5:172-7.
2. Abeloff MD, Beveridge RA, Donehower RC, et al. Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1990;82:570-4.
3. Bonadonna G, Valagussa P. Dose-intense adjuvant treatment of high-risk breast cancer. J Natl Cancer Inst 1990;82:53-4.
4. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-9.
5. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988;6:1368-76.
6. Antman KH. Dose-intensive therapy in breast cancer. In: Armitage JO, Antman KH, eds. High-dose cancer therapy (pharmacology, hematopoietins, stem cells). Baltimore: Williams & Wilkins, 1992; 701-17.
7. Weaver C, Birch R, Schwartzberg L, et al. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. In: Buckner CD, Clift R, eds. Technical and biological components of marrow transplantation. Boston: Kluwer Academic Publishers, 1995;59-85.
8. Ayash LJ, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995;13:2043-9.
9. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-9.
10. Weaver CH, West WH, Schwartzberg LS, et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997;19:661-70.
11. Lazarus HM. Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions. Cancer Invest 1998;16:102-26.
12. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-43.
13. Gianni AM, Siena S, Bregni M, et al. USE 5832-5-year results of high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with ≥10 positive nodes. Los Angeles: American Society of Clinical Oncology, 1995;90.
14. Somlo G, Doroshow J, Forman S, et al. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 1997;15:2882-93.
15. Schwartzberg LS, Birch R, West WH, et al. Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: out-patient administration in community cancer centers. Am J Clin Oncol 1998;21:523-31.
16. Bearman S, Overmoyer B, Bolwell B, et al. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant 1997;20:931-7.
17. Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987;10:387-95.
18. American Joint Committee on Cancer. Manual for staging of cancer. Third ed. Philadelphia: J B Lippincott, 1988.
19. The American Society of Clinical Oncology and American Society of Hematology. Recommended criteria for the performance of bone marrow transplantation. J Clin Oncol 1990;8:563-4.
20. Schwartzberg L, Birch R, Hazelton B, et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1:317-27.
21. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-9.
22. Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997;15: 963-8.
23. Green S, Weiss GR. Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958;53:457-81.
25. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. Journal of the Royal Statistical Society Series A 1972;135: 185-98.
26. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15,71-85.
27. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph nose status and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
28. Antman K, Rowlings P, Vaughan W, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997;15:1870-9.
29. Schwartzberg L, Birch R, Weaver C, et al. Neoadjuvant chemotherapy with or without paclitaxel and high-dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support for locally advanced breast cancer (LABC) [abstract]. Proceedings of the American Society of Clinical Oncology 1996;15:124.
30. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;1:227-41.
31. Clahsen P, van de Velde C, Duval C, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998;16:470-9.